A Phase 1/2 Clinical Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Dystrophic Epidermolysis Bullosa
Phase of Trial: Phase I/II
Latest Information Update: 19 May 2017
At a glance
- Drugs Adipose stem cell therapy Anterogen (Primary)
- Indications Epidermolysis bullosa
- Focus Adverse reactions
- Sponsors Anterogen
- 19 May 2017 Results from this trial published in an Abeona therapeutics Media Release.
- 19 May 2017 According to an Abeona Therapeutics media release, top-line data from this trial will be presented at Society for Investigative Dermatology Conference.
- 27 Dec 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2017.